CD19 (CAR T)
CD19 is a surface glycoprotein belonging to the immunoglobulin (Ig) superfamily that can act as a central positive response regulator in
B cells.1-3 CD19 is expressed during normal B-cell development, and the expression is maintained following malignant transformation of B cells.2-4
The specific expression of CD19 in B-cell lineage lymphomas and leukemias makes CD19 a promising target antigen in B-cell malignancies, like non-Hodgkin lymphomas, through investigational therapies such as chimeric antigen receptor (CAR) T cell therapy.2-4
References
- Scheuermann RH and Racila E. Leuk Lymphoma. 1995;18:385-397. PMID: 8528044
- Wang K, et al. Exp Hematol Oncol. 2012;1:36. PMID: 23210908
- Naddafi R, Davami F. IJMCM. 2015;4:143-151. PMID: 26629482
- Maude SL, et al. Blood. 2015;125:4017-4023. PMID: 25999455
Log In
Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.
Please enter your email address.
You will receive a link to create a new password via email.
Create Account
Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.
